Hims and Hers reaches a deal with Lilly covering GLP-1 medicines, and Hims’ stock rises following the announcement. Under the agreement, Hims says it will stop future compounding of GLP-1 medications such as Lilly’s Zepbound.
Across coverage, outlets frame the news as both a business relationship and a change in Hims’ operating approach. MarketWatch focuses on the impact on Hims’ shares and the specific commitment not to compound GLP-1 products going forward. BioPharma Dive emphasizes that the deal reflects a broader “course change,” describing Hims’ prior sale of knockoff versions of GLP-1 drugs, while also noting other, separate developments in the biopharma sector.